Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Dermatologic 1

Conditions

Lymphoma, T-Cell, Peripheral 2Recurrence 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma 1Hodgkin Disease 1

Interventions

Cyclophosphamide 910Carboplatin 788pembrolizumab 747Paclitaxel 744Bevacizumab 716Cisplatin 709Gemcitabine 621Docetaxel 584Rituximab 558Radiotherapy 548Dexamethasone 511Nivolumab 491Doxorubicin 445Fluorouracil 392Capecitabine 382Etoposide 358Pemetrexed 339Cytarabine 335Oxaliplatin 335Lenalidomide 328Prednisone 327Erlotinib Hydrochloride 323fludarabine phosphate 316Trastuzumab 305Leucovorin 299fludarabine 296Vincristine 288Bortezomib 284Filgrastim 284Cetuximab 277

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × AFM13 × Clear all
NCT05883449 2025-08-20

LuminICE-203

Affimed GmbH

Phase 2 Terminated
25 enrolled 21 charts
Lymphoid

Hodgkin Disease, Recurrence, Lymphoma, T-Cell, Peripheral

NCT04101331 2024-11-05

REDIRECT

Affimed GmbH

Phase 2 Completed
108 enrolled 24 charts
Lymphoid

Lymphoma, T-Cell, Peripheral

NCT03192202 2023-07-20

AFM13 in Relapsed/Refractory Cutaneous Lymphomas

Columbia University

Phase 1/2 Completed
18 enrolled 9 charts
DermatologicLymphoid

Lymphoma, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡